keyword
MENU ▼
Read by QxMD icon Read
search

ezitimibe

keyword
https://www.readbyqxmd.com/read/21687351/antihyperlipidemic-effect-of-trichilia-connaroides-in-hypercholesterolemic-rats-and-its-possible-mechanism
#1
Prasanna Gurunath Subbarao, Purnima Ashok
OBJECTIVES: The primary objective of this study was to investigate the antihyperlipidemic effect of the chloroform (CETC) and methanol (METC) extracts of leaves of Trichilia connaroides in hypercholesterolemic rats and, subsequently, to evaluate the possible mechanism of its antihyperlipidemic effect. MATERIALS AND METHODS: The antihyperlipidemic activity of CETC and METC (100 mg/kg) in hypercholesterolemic rats was investigated by recording the serum lipid profile after a month-long oral treatment of these extracts...
April 2011: Journal of Pharmacy & Bioallied Sciences
https://www.readbyqxmd.com/read/19500568/regulation-of-steroid-5-alpha-reductase-type-2-srd5a2-by-sterol-regulatory-element-binding-proteins-and-statin
#2
Young-Kyo Seo, Bing Zhu, Tae-Il Jeon, Timothy F Osborne
In this study, we show that sterol regulatory element binding proteins (SREBPs) regulate expression of Srd5a2, an enzyme that catalyzes the irreversible conversion of testosterone to dihydroxytestosterone in the male reproductive tract and is highly expressed in androgen-sensitive tissues such as the prostate and skin. We show that Srd5a2 is induced in livers and prostate from mice fed a chow diet supplemented with lovastatin plus ezitimibe (L/E), which increases the activity of nuclear SREBP-2. The three fold increase in Srd5a2 mRNA mediated by L/E treatment was accompanied by the induction of SREBP-2 binding to the Srd5a2 promoter detected by a ChIP-chip assay in liver...
November 1, 2009: Experimental Cell Research
https://www.readbyqxmd.com/read/16767301/-treatment-of-dyslipidemia-how-and-when-to-combine-lipid-lowering-drugs
#3
REVIEW
Isio Schulz
Familial combined hyperlipidemia (FCH) is a frequent familial lipid disorder associated with insulin resistance, low HDL cholesterol, high triglycerides and cholesterol levels with variable phenotypes within the same family. FCH is linked to a high risk for cardiovascular diseases. Treatment goals for lipid abnormalities are changing in recent years. Lowering elevated levels of LDL e Non HDL-cholesterol levels are primary targets of therapy. Lower LDL-C than 70 mg/dL seems to be useful to lower cardiovascular risk in patients with very high risk...
April 2006: Arquivos Brasileiros de Endocrinologia e Metabologia
https://www.readbyqxmd.com/read/12822207/-new-antilipemics-prospects
#4
REVIEW
Michel Farnier
The field of new lipid-lowering drug research is very active, with researchers, looking to make the currently available drugs more powerful and safer, and to develop new classes of drugs. Among the statins, development has gone the farthest for rosuvastatin and pitavastatin. Colesevelam is a new bile acid sequestrant with a better digestive tolerance. Among the new classes of drugs, the most promising molecules are the cholesterol absorption inhibitors--with ezetimibe as the first in line--and the PPAR-alpha and PPAR-gamma activators...
January 2003: Thérapie
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"